Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 709

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 9A
Chunk 709
---
 Exercise of public warrants and common warrants into common stock

    263,866

    -

    Common stock underlying outstanding options (2024 Plan)

    64,948

    504

    1,567,308

    19,691

Restricted common stock can
be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares are excluded
from the computation of basic loss per share as these shares are not considered outstanding until vested. No unvested restricted common
stock awards were issued or outstanding during the years ended December 31, 2024 or 2023. 

NOTE 5 – PROPERTY AND
EQUIPMENT

Property and equipment, net, consisted of the
following as of December 31, 2024 and 2023:

    December 31,  
    December 31, 

    2024  
    2023 

    (Successor)  
    (Predecessor) 
  
    Laboratory equipment 
    $2,507,839  
    $2,507,839 
  
    Computers 
     38,323  
     38,323 
  
    Furniture 
     8,429  
     8,429 
  
    Total cost 
     2,554,591  
     2,554,591 
  
    Less: accumulated depreciation 
     (2,026,070) 
     (1,587,889)
  
    Property and equipment, net 
    $528,521  
    $966,702 

Depreciation expense for
the period from February 14, 2024 through December 31, 2024 for Successor was $400,825. Predecessor depreciation expense for the period
January 1, 2024 through February 13, 2024 and for the year ended December 31, 2023 was $37,356 and $460,722, respectively.

F-16

NOTE 6 – ACCRUED LIABILITIES

Accrued liabilities consisted of the following as of December 31, 2024
and 2023:

    December 31,  
    December 31, 

    2024  
    2023 

    (Successor)  
    (Predecessor) 
  
    Employee-related liabilities 
    $244,302  
    $68